PepGen (PEPG) Competitors $6.48 -0.14 (-2.11%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PEPG vs. LQDA, DNTH, ABCL, ANNX, ERAS, PCRX, ABUS, OCS, MBX, and IMNMShould you be buying PepGen stock or one of its competitors? The main competitors of PepGen include Liquidia (LQDA), Dianthus Therapeutics (DNTH), AbCellera Biologics (ABCL), Annexon (ANNX), Erasca (ERAS), Pacira BioSciences (PCRX), Arbutus Biopharma (ABUS), Oculis (OCS), MBX Biosciences (MBX), and Immunome (IMNM). These companies are all part of the "pharmaceutical preparations" industry. PepGen vs. Liquidia Dianthus Therapeutics AbCellera Biologics Annexon Erasca Pacira BioSciences Arbutus Biopharma Oculis MBX Biosciences Immunome PepGen (NASDAQ:PEPG) and Liquidia (NASDAQ:LQDA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment. Which has higher earnings and valuation, PEPG or LQDA? Liquidia has higher revenue and earnings than PepGen. Liquidia is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPepGenN/AN/A-$78.63M-$3.30-1.96Liquidia$17.49M48.21-$78.50M-$1.57-6.99 Does the MarketBeat Community prefer PEPG or LQDA? Liquidia received 182 more outperform votes than PepGen when rated by MarketBeat users. However, 84.21% of users gave PepGen an outperform vote while only 67.81% of users gave Liquidia an outperform vote. CompanyUnderperformOutperformPepGenOutperform Votes1684.21% Underperform Votes315.79%LiquidiaOutperform Votes19867.81% Underperform Votes9432.19% Do analysts recommend PEPG or LQDA? PepGen presently has a consensus price target of $19.33, indicating a potential upside of 198.35%. Liquidia has a consensus price target of $24.67, indicating a potential upside of 124.65%. Given PepGen's higher probable upside, analysts clearly believe PepGen is more favorable than Liquidia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Liquidia 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.90 Which has more risk and volatility, PEPG or LQDA? PepGen has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Do institutionals & insiders have more ownership in PEPG or LQDA? 58.0% of PepGen shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 4.6% of PepGen shares are owned by insiders. Comparatively, 30.1% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is PEPG or LQDA more profitable? PepGen has a net margin of 0.00% compared to Liquidia's net margin of -755.46%. PepGen's return on equity of -62.74% beat Liquidia's return on equity.Company Net Margins Return on Equity Return on Assets PepGenN/A -62.74% -50.37% Liquidia -755.46%-183.57%-74.19% Does the media refer more to PEPG or LQDA? In the previous week, Liquidia had 1 more articles in the media than PepGen. MarketBeat recorded 1 mentions for Liquidia and 0 mentions for PepGen. Liquidia's average media sentiment score of 0.47 beat PepGen's score of 0.00 indicating that Liquidia is being referred to more favorably in the news media. Company Overall Sentiment PepGen Neutral Liquidia Neutral SummaryLiquidia beats PepGen on 11 of the 18 factors compared between the two stocks. Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEPG vs. The Competition Export to ExcelMetricPepGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$211.18M$7.02B$5.32B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio-1.9610.75121.3415.54Price / SalesN/A396.531,497.9292.41Price / CashN/A47.4339.6734.18Price / Book1.425.604.755.07Net Income-$78.63M$153.56M$118.54M$225.38M7 Day Performance-15.63%-1.46%-0.39%0.07%1 Month Performance-27.11%15.32%6.05%3.93%1 Year Performance27.06%43.07%38.13%32.51% PepGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PEPGPepGen2.5419 of 5 stars$6.48-2.1%$19.33+198.4%+27.1%$211.18MN/A-1.9672LQDALiquidia3.8829 of 5 stars$10.98+1.2%$24.67+124.7%+66.6%$843.15M$17.49M-6.9950Upcoming EarningsDNTHDianthus Therapeutics1.4672 of 5 stars$28.01+0.5%$45.14+61.2%+133.4%$822.65M$2.83M-5.0680Positive NewsABCLAbCellera Biologics2.072 of 5 stars$2.73flat$10.33+278.5%-33.7%$804.45M$38.03M-5.06586Upcoming EarningsANNXAnnexon1.457 of 5 stars$7.28-0.5%$15.80+117.0%+203.3%$769.13MN/A-5.9260ERASErasca2.6255 of 5 stars$2.72+5.0%$6.10+124.3%+19.8%$768.40MN/A-2.96126Gap UpPCRXPacira BioSciences4.8183 of 5 stars$16.57-0.2%$24.20+46.0%-41.5%$764.32M$690.31M12.65720Upcoming EarningsNews CoveragePositive NewsABUSArbutus Biopharma2.3082 of 5 stars$3.96+2.9%$5.25+32.6%+115.2%$725.87M$10.06M-8.8073Upcoming EarningsOCSOculis2.1656 of 5 stars$17.88+4.1%$29.20+63.3%+96.5%$724.14M$980,000.00-9.312Gap DownHigh Trading VolumeMBXMBX Biosciences2.4182 of 5 stars$22.46-1.9%$37.25+65.9%N/A$715.44MN/A0.0036IMNMImmunome2.4973 of 5 stars$11.59+1.0%$29.00+150.2%+35.2%$695.98M$14.02M-1.5140Short Interest ↓Gap Up Related Companies and Tools Related Companies Liquidia Alternatives Dianthus Therapeutics Alternatives AbCellera Biologics Alternatives Annexon Alternatives Erasca Alternatives Pacira BioSciences Alternatives Arbutus Biopharma Alternatives Oculis Alternatives MBX Biosciences Alternatives Immunome Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PEPG) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
